Therapeutic Antibodies – News and Features

Researchers have discovered that combining immunotherapy and chemotherapy can overcome treatment resistance in a subset of lung cancer patients.

This article explores the revolution in new drug modalities and the challenges around effective data strategies to support AI efforts.

Bioprocessing involves the production of a high-value-added product from a living source. In this article, the stages of bioprocessing are described, with a focus on the central piece of this concept: the bioreactor.

Researchers found that the immunotherapy drug pembrolizumab significantly extends the cancer-free period for patients with high-risk muscle-invasive bladder cancer after surgery.

Interim data from the Phase I dose escalation part of the mRNA cancer immunotherapy (mRNA-4359), show promise in patients with advanced solid cancers.

The DESTINY-Breast12 trial revealed that trastuzumab deruxtecan (T-DXd) effectively targets brain metastases in HER2-positive breast cancer. T-DXd offers a promising new option for patients with advanced disease.

A study challenges the amyloid plaque theory in Alzheimer’s, showing that increased levels of the brain protein Aβ42 are as strongly correlated with slower cognitive decline as reductions in amyloid plaques.

Researchers have identified a mechanism by which triple-negative breast cancer (TNBC) cells resist immunotherapy. By studying the role of ceramide synthase 4, they restored sensitivity to immunotherapy in a preclinical model.

The monoclonal antibody SC27 effectively neutralizes numerous SARS-CoV-2 variants and related coronaviruses. SC27 targets multiple sites on the spike protein, showing broad protection in lab tests and animal models.

A light-controlled "appetizer" that stimulates macrophages can increase their appetite for cancer cells, finds a new study.